#1 Clinical Trials Search in Europe

Ecoo15

Clinical trials are underway to evaluate the effectiveness of a new vaccine called ExPEC9V in preventing invasive extraintestinal pathogenic Escherichia coli (E. coli) disease in older adults. This vaccine, which contains the active substance ECOO15 among others, is being tested in adults aged 60 and older with a history of urinary tract infections. The trials aim to assess the vaccine’s ability to prevent serious E. coli infections and its safety profile.

Table of Contents

What is ECOO15?

ECOO15 is one of the active components in a new vaccine called ExPEC9V (also known as JNJ-78901563). This vaccine is being developed to prevent invasive diseases caused by certain types of Escherichia coli bacteria[1]. E. coli is a common bacteria found in the human gut, but some strains can cause serious infections outside the intestines, such as in the urinary tract or bloodstream.

Purpose of ECOO15

ECOO15 is specifically designed to target the O15 serotype of extraintestinal pathogenic E. coli (ExPEC). ExPEC are strains of E. coli that can cause infections outside the intestinal tract. The ExPEC9V vaccine, which includes ECOO15, aims to prevent invasive extraintestinal pathogenic Escherichia coli disease (IED)[2]. This can include serious conditions such as:

  • Urinary tract infections (UTIs): Infections in any part of the urinary system
  • Bacteremia: Presence of bacteria in the blood
  • Sepsis: A life-threatening condition caused by the body’s response to an infection
  • Pyelonephritis: A serious kidney infection

Target Population

The ExPEC9V vaccine, which includes ECOO15, is being studied in adults aged 60 years and older. This population is particularly targeted because:

  • They have a higher risk of developing invasive E. coli infections
  • They often have a history of urinary tract infections
  • Their immune systems may be less effective at fighting off infections
Specifically, the vaccine is being tested in people who have had a urinary tract infection in the past 2 years and have at least one additional risk factor for invasive E. coli disease[2].

Clinical Trials

ECOO15, as part of the ExPEC9V vaccine, is currently being studied in Phase 3 clinical trials. These are large-scale studies designed to test the effectiveness and safety of the vaccine. Two important trials are:

  1. A study comparing ExPEC9V with a high-dose influenza vaccine in adults 65 years and older[1].
  2. A study testing ExPEC9V against a placebo in adults 60 years and older with a history of urinary tract infections[2].
These trials aim to determine how well the vaccine prevents invasive E. coli disease and how safe it is for use in older adults.

Potential Benefits

If successful, the ExPEC9V vaccine containing ECOO15 could provide several benefits:

  • Prevention of invasive E. coli infections, including serious UTIs and bloodstream infections
  • Reduction in hospitalizations related to E. coli infections
  • Decreased need for antibiotics, potentially helping to combat antibiotic resistance
  • Improved quality of life for older adults who are prone to recurrent UTIs

Safety and Side Effects

As with any vaccine, safety is a crucial consideration. The clinical trials are carefully monitoring for any side effects. Common side effects of vaccines can include:

  • Pain, redness, or swelling at the injection site
  • Mild fever
  • Fatigue
  • Headache
The trials are specifically looking at both solicited (expected) and unsolicited (unexpected) adverse events, as well as any serious adverse events that may occur[2]. This thorough monitoring helps ensure the vaccine’s safety before it can be approved for general use.

Conclusion

ECOO15, as a component of the ExPEC9V vaccine, represents a promising approach to preventing serious E. coli infections in older adults. While still in the testing phase, this vaccine could potentially provide significant health benefits to a vulnerable population. As always, it’s important to discuss any new medical treatments or vaccines with your healthcare provider to determine if they are appropriate for your individual health needs.

Aspect Details
Vaccine Name ExPEC9V (JNJ-78901563)
Target Population Adults aged 60 years and older with a history of urinary tract infections
Main Objective Prevent invasive extraintestinal pathogenic E. coli disease
Administration Intramuscular injection
Key Components ECOO1A, ECOO2, ECOO4, ECOO6A, ECOO15, ECOO16, ECOO18A, ECOO25B, ECOO75
Trial Phase Phase 3
Primary Endpoints Prevention of first IED event caused by ExPEC serotypes; Antibody response to vaccine antigens
Secondary Endpoints Prevention of UTIs, pyelonephritis, and hospitalized IED events; Safety and reactogenicity; Quality of life impact

FAQ

  • What is ExPEC9V? ExPEC9V is a vaccine being developed to prevent invasive extraintestinal pathogenic Escherichia coli (E. coli) disease. It contains multiple components targeting different E. coli serotypes, including ECOO15.
  • Who is being included in these clinical trials? The trials are focusing on adults aged 60 years and older who have a history of urinary tract infections in the past 2 years. Some trials also include adults 65 years and older.
  • What is the main goal of these clinical trials? The main goal is to evaluate the efficacy of ExPEC9V in preventing invasive E. coli disease, as well as to assess its safety, immunogenicity (ability to provoke an immune response), and impact on quality of life.
  • How is the vaccine administered? ExPEC9V is administered as an intramuscular injection. In some trials, it's being tested alongside other vaccines like the high-dose quadrivalent influenza vaccine.
  • What are the potential benefits of this vaccine? If successful, ExPEC9V could help prevent serious E. coli infections, including those causing urinary tract infections, bloodstream infections, and other invasive diseases in older adults who are at higher risk for these conditions.

Ongoing Clinical Trials on Ecoo15

  • Study on the Safety and Immune Response of JNJ-78901563 and High-dose Influenza Vaccine in Preventing E. coli Infections in Adults Aged 65 and Older

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Poland

  • Study of ExPEC9V vaccine for preventing invasive E.

    Not recruiting

    3 1
    Investigated diseases:
    Investigated drugs:
    Czechia Denmark France Germany The Netherlands Spain +1

Glossary

  • Extraintestinal pathogenic Escherichia coli (ExPEC): A type of E. coli bacteria that can cause infections outside the intestines, such as urinary tract infections, bloodstream infections, and other serious diseases.
  • Invasive E. coli Disease (IED): A serious infection caused by E. coli bacteria that spreads beyond the initial site of infection, such as into the bloodstream or other normally sterile body sites.
  • Immunogenicity: The ability of a substance, such as a vaccine, to provoke an immune response in the body.
  • Serotype: A distinct variation within a species of bacteria, identified by the cell surface antigens. ExPEC9V targets multiple E. coli serotypes including O1, O2, O4, O6, O15, O16, O18, O25, and O75.
  • Urinary Tract Infection (UTI): An infection affecting any part of the urinary system, including kidneys, bladder, and urethra. UTIs are often caused by E. coli bacteria.
  • Pyelonephritis: A type of urinary tract infection that affects one or both kidneys.
  • Bacteremia: The presence of bacteria in the bloodstream, which can lead to serious infections throughout the body.
  • Sepsis: A life-threatening condition that occurs when the body's response to infection causes widespread inflammation and organ failure.

References

  1. http://clinicaltrials.eu/trial-id/2023-504168-40-00
  2. http://clinicaltrials.eu/trial/study-on-jnj-78901563-vaccine-for-preventing-invasive-e-coli-disease-in-adults-60-with-recent-urinary-tract-infections/